Challenges and complications in juvenile localized scleroderma: A practical approach

2024-9-1

A review of the advances in understanding the genetic basis of spondylarthritis and emerging clinical benefit

2024-9-1

Antiphospholipid syndrome in children

2024-8-1

Interferonopathies: From concept to clinical practice

2024-8-1

The importance of functional genomics studies in precision rheumatology

2024-8-1

Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice

2024-8-1

Utility of polygenic risk scores to aid in the diagnosis of rheumatic diseases

2024-7-1

Exploring the contribution of genetics on the clinical manifestations of systemic lupus erythematosus

2024-7-1

Genetics of osteoarthritis

2024-7-1

A lifelong journey: Long-term perspectives on Juvenile Idiopathic Arthritis

2024-7-1

Biology of HLA class I associated inflammatory diseases

2024-7-1

“Inflammatory or non-inflammatory pain in inflammatory arthritis – How to differentiate it?”

2024-7-1

Genetics of vasculitis

2024-7-1

Management of JIA associated uveitis

2024-7-1

Enthesopathies – Mechanical, inflammatory or both?

2024-7-1

Pharmacogenetics of therapies in rheumatoid arthritis: An update

2024-7-1

Immunopathology of inflammatory rheumatic diseases

2024-7-1

Insights into the genetic landscape of systemic sclerosis

2024-7-1

Genetics of rheumatoid arthritis

2024-7-1

Capillaroscopy in the daily clinic of the pediatric rheumatologist

2024-7-1

The inequity of global healthcare in pediatric rheumatology

2024-7-1

38.3 Primary Immunodeficiencies: When is it not just “JIA”

2024-6-1

Nutrients and Nocioception: Diet in the management of pain

2024-6-1

CARD9 in the pathogenesis of axial spondyloarthritis

2024-6-1

Exploring the role of gut microbes in spondyloarthritis: Implications for pathogenesis and therapeutic strategies

2024-6-1

Use of Mendelian randomization to assess the causal status of modifiable exposures for rheumatic diseases

2024-6-1

How to treat monogenic SLE?

2024-6-1

Painful Raynaud's mimics

2024-5-1

Editorial Board

2024-5-1

Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases

2024-4-15

Problems with “Problems with opioids beyond misuse”

2024-4-1

Myofascial pain – A major player in musculoskeletal pain

2024-4-1

Immune checkpoints in autoimmune vasculitis

2024-4-1

TNFR2 signalling in inflammatory diseases

2024-3-27

Response to kollas. Letter to the editor, “problems with opioids beyond misuse”

2024-3-1

Pain mechanisms for the practicing rheumatologist

2024-3-1

Editorial Board

2024-3-1

Dendritic cells and antigen-specific immunotherapy in autoimmune rheumatic diseases

2024-3-1

Pain syndromes

2024-3-1

Problems with opioids - beyond misuse

2024-3-1

Cervicogenic headache – How to recognize and treat

2024-2-1

Femoroacetabular impingement – What the rheumatologist needs to know

2024-2-1

B cell activation and autoantibody production in autoimmune diseases

2024-2-1

Practical approaches for clinicians in chronic pain management: Strategies and solutions

2024-2-1

“Fibromyalgia – are there any new approaches?”

2024-2-1

Non-coding DNA variants for risk in lupus

2024-2-1

Granzyme K+ CD8 T cells in autoimmunity

2024-2-1

Editorial Board

2023-12-1

Systemic lupus erythematosus and glucocorticoids: A never-ending story?

2023-12-1

Translational implications of newly characterized pathogenic pathways in systemic lupus erythematosus

2023-12-1